FLT3 and acute myeloid leukemia: Using the Beat AML trial cohort37, we found significant co-expression of CDX2 and FLT3 in AML patients, as well as increased CDX2 expression in FLT3-internal tandem duplication (ITD)-positive samples compared with FLT3-ITD-negative samples (Supplementary Fig. 3b, c).